Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
Washington Post probes cyberattack on journalists' email accounts
Market Updates

Washington Post probes cyberattack on journalists' email accounts

[Newspaper Kiosks in a Row] CatLane/iStock Unreleased via Getty Images The Washington Post is investigating a cybersecurity breach that compromised the email accounts of several of its journalists, in...

  • June 15, 2025 01:10 PM PDT
  • EODHD
Washington Post investigating cyberattack on journalists, WSJ reports
Market Updates

Washington Post investigating cyberattack on journalists, WSJ reports

(Reuters) -A cyberattack on the Washington Post compromised the email accounts of several journalists and was most likely the work of a foreign government, the Wall Street Journal reported on Sunday....

  • June 15, 2025 01:00 PM PDT
  • EODHD
Fed Interest Rate Decision, Economic Data, Lennar Earnings, and What Else to Watch This Week
Market Updates

Fed Interest Rate Decision, Economic Data, Lennar Earnings, and What Else to Watch This Week

The main event of the coming shortened trading week is the two-day Federal Open Market Committee’s monetary-policy meeting. Continue Reading View Comments

  • June 15, 2025 11:00 AM PDT
  • EODHD
Estée Lauder : Chairman Emeritus Leonard Lauder Passes Away At Age Of 92
Market Updates

Estée Lauder : Chairman Emeritus Leonard Lauder Passes Away At Age Of 92

(RTTNews) - The Estée Lauder Companies Inc. (EL) announced that Chairman Emeritus Leonard Lauder passed away on June 14, at the age of 92. Lauder was born in 1933 in New York City, the oldest son of E...

  • June 15, 2025 10:30 AM PDT
  • EODHD
Estee Lauder chairman emeritus Leonard Lauder dies, company says
Market Updates

Estee Lauder chairman emeritus Leonard Lauder dies, company says

(Reuters) -Estee Lauder said on Sunday that its chairman emeritus, Leonard Lauder, has died at the age of 92.

  • June 15, 2025 10:10 AM PDT
  • EODHD
Estee Lauder Chairman Emeritus Leonard Lauder dies at 92
Market Updates

Estee Lauder Chairman Emeritus Leonard Lauder dies at 92

(Reuters) -Estee Lauder said on Sunday that its chairman emeritus, Leonard Lauder, died on Satuday at the age of 92. Lauder joined the company in 1958 and played a key role in transforming the busines...

  • June 15, 2025 10:07 AM PDT
  • EODHD
Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment
Market Updates

Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment

(RTTNews) - Sanofi (SNYNF, SNY) and Regeneron Pharmaceuticals Inc. (REGN) presented positive results from the EVEREST Phase 4 study involving adults with severe chronic rhinosinusitis with nasal polyp...

  • June 15, 2025 09:25 AM PDT
  • EODHD
CAR 截止日期提醒:廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 - CAR
Market Updates

CAR 截止日期提醒:廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 - CAR

紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事由:全球投資人權益律師事務所 Rosen Law Firm 提醒在 2024 年 2 月 16 日至 2025 年 2 月 10 日(含首尾兩天,簡稱「集體訴訟期間」)期間購買 Avis Budget Group, Inc....

  • June 15, 2025 08:32 AM PDT
  • EODHD
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clini
Market Updates

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clini

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median...

  • June 15, 2025 07:56 AM PDT
  • EODHD
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Market Updates

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median...

  • June 15, 2025 07:45 AM PDT
  • EODHD